This report was first published by Endpoints News. To see the original version, click here
Neurology has long been seen as a high-risk investment.
Biopharma’s understanding of how the brain works is still rudimentary compared with that of other organs, as is its knowledge of what drives specific neurological diseases. Patient populations are also heterogeneous, so success in early- or mid-stage trials doesn’t necessarily translate into wins later in the clinic.
您已閱讀5%（463字），剩余95%（9235字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。